SEC Form 3 · accession 0001104659-15-070685
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Blake M Paterson
Officer — CEO and President · Director
Period of report
Oct 14, 2015
Accepted (ET)
Oct 14, 2015 · 5:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 56,071 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.68 | holding | — | — | — | — | Jan 31, 2022 | Common Stock | 107,142 | — | D |
| Stock Option (Right to Buy) | $16.80 | holding | — | — | — | Jul 10, 2014 | Jan 31, 2024 | Common Stock | 54,353 | — | D |
Explanation of responses
- F1The Stock Option vested in three equal installments on February 23, 2013, 2014 and 2015.
Remarks
Exhibit 24 - Power of Attorney